Abu Dhabi Biobank Launched by DoH and M42 Features the Region’s Largest Hybrid Cord Blood Bank

A partnership between DoH and M42 aims to revolutionize therapeutic access and biobanking excellence in the region.

Abu Dhabi Biobank Launched by DoH and M42 Features the Region’s Largest Hybrid Cord Blood Bank
Credit: M42
Advertisement img

Highlights

  • The Abu Dhabi Biobank, launched by DoH and M42, introduces the region’s largest hybrid cord blood bank.
  • The initiative aims to improve treatment access, enhance survival rates, and reduce healthcare costs.
  • Announced at the Abu Dhabi Global Healthcare Week 2024, the Biobank is a cornerstone of the emirate’s life sciences strategy.

The Department of Health – Abu Dhabi (DoH) and M42 have launched the Abu Dhabi Biobank, featuring the region’s largest hybrid cord blood bank, aiming to enhance treatment access, survival rates, and reduce healthcare costs. Announced during the inaugural Abu Dhabi Global Healthcare Week 2024, this initiative seeks to position Abu Dhabi as a leading life sciences hub. The Biobank will support therapeutic treatments, medical research, and drug discovery, contributing to personalized and preventative healthcare.

Dr. Noura Khamis Al Ghaithi emphasized the Biobank’s potential to accelerate drug discovery and improve patient outcomes through advanced biobanking of cord blood and other biological specimens. The facility will be available at key healthcare entities, providing expectant parents the option to preserve newborns’ stem cells. With a capacity to store 100,000 cord blood samples and five million human samples, the Biobank aims to create a vast dataset for global health improvements.

Ashish Koshy highlighted M42’s commitment to advancing health through innovative therapies and research, reinforcing Abu Dhabi’s role as a global health-tech hub. The Biobank’s advanced infrastructure ensures long-term preservation and viability of samples for research and therapeutic use.

Featured Partners